Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fnins.2025.1651016 http://scihub22266oqcxt.onion/10.3389/fnins.2025.1651016 C12528170!12528170 !41113438     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41113438 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Front+Neurosci 2025 ; 19 (?): 1651016 Nephropedia Template TP {{tp|p=41113438 |t=2025. Human in vivo assessment of ketamine binding of the serotonin transporter-follow up at a higher dose |pdf=|usr=}}{{41113438 }} gab.com Text Human in vivo assessment of ketamine binding of the serotonin transporter-follow up at a higher dose JO: Front Neurosci http://www.kidney.de/pget.php?&tw=1&pmid=41113438 #FOAvip Ketamine is a rapid-acting antidepressant approved in the indication of treatment-resistant depression. As its clinical use expands, identifying underlying molecular mechanisms is essential. The serotonin transporter (SERT) is well known as a primary mechanism of several classes of monoaminergic antidepressants. Binding of ketamine to SERT has been observed in vitro and in animal studies with macaque monkeys using positron emission tomography (PET). We previously reported that a 0.5?mg/kg body weight dose of ketamine did not significantly bind to SERT in healthy human subjects assessed with PET but observed a positive trend between binding and ketamine plasma levels. Based on this finding, we hypothesized that a higher dose (0.8?mg/kg) would result in measurable SERT occupancy. Here, 10 healthy male participants were measured twice with [(11)C]DASB PET to test SERT occupancy following administration of 0.8?mg/kg body weight ketamine in four selected SERT rich regions amygdala, putamen, caudate and thalamus. Further, we implemented a bolus-plus-infusion radioligand infusion protocol and optimized the timing of the ketamine infusion. Contrary to our hypothesis, ketamine SERT occupancy did not significantly differ from zero, and the area under the curve of ketamine and norketamine plasma levels was not correlated with occupancy. These results suggest that even at doses up to 0.8?mg/kg, ketamine does not appreciably bind to SERT in humans, aligning with clinical observations that ketamine is routinely combined with serotonergic agents. CLINICAL TRIAL REGISTRATION: http://clinicaltrials.gov, identifier, NCT02582398. EUDAMED number, CIV-AT-13-01-009583. Twit Text FOAVip Human in vivo assessment of ketamine binding of the serotonin transporter-follow up at a higher dose ????Front Neurosci http://www.kidney.de/pget.php?&tw=1&pmid=41113438 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41113438 #FOAvip English Wikipedia <ref>{{Cite pmid|41113438 }}</ref> Human in vivo assessment of ketamine binding of the serotonin transporter-follow up at a higher dose #MMPMID41113438 Schlosser G ; Murga? M ; Godbersen GM ; Reichel S ; Silberbauer L ; Nics L ; Winkler D ; Stimpfl T ; Hacker M ; Kasper S ; Rujescu D ; Lanzenberger R ; Spies M Front Neurosci 2025[]; 19 (?): 1651016 PMID41113438 show ga Ketamine is a rapid-acting antidepressant approved in the indication of treatment-resistant depression. As its clinical use expands, identifying underlying molecular mechanisms is essential. The serotonin transporter (SERT) is well known as a primary mechanism of several classes of monoaminergic antidepressants. Binding of ketamine to SERT has been observed in vitro and in animal studies with macaque monkeys using positron emission tomography (PET). We previously reported that a 0.5?mg/kg body weight dose of ketamine did not significantly bind to SERT in healthy human subjects assessed with PET but observed a positive trend between binding and ketamine plasma levels. Based on this finding, we hypothesized that a higher dose (0.8?mg/kg) would result in measurable SERT occupancy. Here, 10 healthy male participants were measured twice with [(11)C]DASB PET to test SERT occupancy following administration of 0.8?mg/kg body weight ketamine in four selected SERT rich regions amygdala, putamen, caudate and thalamus. Further, we implemented a bolus-plus-infusion radioligand infusion protocol and optimized the timing of the ketamine infusion. Contrary to our hypothesis, ketamine SERT occupancy did not significantly differ from zero, and the area under the curve of ketamine and norketamine plasma levels was not correlated with occupancy. These results suggest that even at doses up to 0.8?mg/kg, ketamine does not appreciably bind to SERT in humans, aligning with clinical observations that ketamine is routinely combined with serotonergic agents. CLINICAL TRIAL REGISTRATION: http://clinicaltrials.gov, identifier, NCT02582398. EUDAMED number, CIV-AT-13-01-009583. ?Human in vivo assessment of ketamine binding of the serotonin transpor(epmc).pdf DeepDyve Pubget Overpricing